Publication: 2194

Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831
      QxMD      Google Scholar   
Citation:
J Clin Oncol vol 32 (33) 3744-3752
Year:
2014
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Meta-Analysis
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
4
Parents:
703  
Children:
None
Program:
OGC
Primary Committee:
Breast
Sec. Committees:
   
Pharmas:
 
Grants:
U10CA180821, U10CA180882 , UG1 CA189867, U10 CA012027, U10 CA180821, U10 CA069651, P30 CA015083, U10 CA180882, R01 CA129949, U10 CA069974, U10 CA025224, U10 CA180888, U10 CA037377  
Corr. Author:
 
Authors:
                                 
Networks:
 
Study
NCCTG-N9831
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords:
Bc5, ORIGINAL REPORTS, Breast Cancer